Vicarious Surgical Faces NYSE Non-Compliance Notice

Vicarious Surgical ( (RBOT) ) has shared an update.

On April 10, 2025, Vicarious Surgical received a notice from the NYSE indicating non-compliance with listing standards due to its market capitalization and stockholders’ equity both being below $50 million. The company has 45 days to submit a compliance plan to the NYSE, which, if accepted, will allow its stock to continue trading with a ‘.BC’ designation indicating below-criteria status. This notice does not affect the company’s operations or SEC reporting obligations, and Vicarious Surgical is exploring options to regain compliance.

Spark’s Take on RBOT Stock

According to Spark, TipRanks’ AI Analyst, RBOT is a Underperform.

The overall score for Vicarious Surgical’s stock is 38, reflecting significant financial challenges due to its early-stage status with zero revenue and high cash burn. Technical indicators point to bearish momentum, while valuation remains unattractive with a negative P/E. The earnings call highlighted both strategic advancements and operational delays, balancing the outlook slightly. The company’s future relies on successful clinical trials and managing supply chain issues.

To see Spark’s full report on RBOT stock, click here.

More about Vicarious Surgical

Vicarious Surgical is a next-generation robotics company founded in 2014, specializing in developing disruptive technology aimed at enhancing surgical efficiency, improving patient outcomes, and reducing healthcare costs. The company employs proprietary human-like surgical robots to enable minimally invasive surgery and is supported by notable investors such as Bill Gates and Khosla Ventures. Headquartered in Waltham, Massachusetts, Vicarious Surgical is focused on transforming robotic surgery.

YTD Price Performance: -60.77%

Average Trading Volume: 35,778

Technical Sentiment Signal: Strong Buy

Current Market Cap: $33.86M

See more data about RBOT stock on TipRanks’ Stock Analysis page.